{"schema_version":"secwatch.filing_event.v1","accession":"0001776111-25-000007","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.955035+00:00","generated_at":"2026-05-17T08:20:27.663896+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"MBX Biosciences doses first participant in Phase 1 trial of obesity drug MBX 4291","bullets":["Phase 1 trial is randomized, double-blind, placebo-controlled; Part A: 5 SAD cohorts (8 each, 3:1 randomization).","Part B: 3 MAD cohorts (4 weekly doses, 8 each, 3:1 randomization); plus optional 12-week MAD cohorts (30 each, 2:1).","Topline results anticipated in 2027; preclinical data support once-monthly dosing and improved GI tolerability.","MBX 4291 is a long-acting GLP-1/GIP co-agonist prodrug for obesity, designed for best-in-class weight loss."],"urls":{"canonical":"https://secwatch.observer/filing/0001776111-25-000007","json":"https://secwatch.observer/filing/0001776111-25-000007.json","markdown":"https://secwatch.observer/filing/0001776111-25-000007.md","text":"https://secwatch.observer/filing/0001776111-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000177611125000007/0001776111-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000177611125000007/mbx-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:20:27.663896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}